Trial Profile
Genetically Modified T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti EGFR chimeric antigen receptor T cell therapy CARSGEN Therapeutics (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 25 Jan 2016 Results from this trial are expected in December 2016, according to a CARsgen Therapeutics media release.
- 01 Oct 2015 New trial record